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we update some aspects of the obesity including the relationship 
between the adipose tissue and inflammation.
Obesity definition and diagnosisAdipose tissue, almost more than any other tissue, is increasingly being considered contributing to both human well-being and disease processes.
Obesity can be defined as an excess of body fat. Its clinical 
management is complex and frequently unsuccessful [4]. A 
surrogate marker for body fat content is the Body Mass Index 
(BMI), which is widely used both for epidemiological studies 
and clinical evaluations [5]. Among children and adolescents 
age and gender cut-off values should be used [6]. A better way to 
define obesity should be in terms of Body Fat Percentage (BF%) 
that can be measured by different techniques, from skin-fold 
measurements to magnetic resonance [7]. Other frequently used 
methods for determining BF% include Bioelectrical Impedance 
Analysis (BIA), and Dual-Energy X-Ray Absorptiometry (DEXA), 
underwater weighing and Air Displacement Plethysmography 
(ADP). When BF% determination is not available, BMI is the most 
frequently used surrogate measure of adiposity. However, BMI 
exhibits notable inaccuracies not precisely reflecting body fat, for instance, the changes in body composition in the different 
periods of life or the sexual dimorphism characteristics of body 
adiposity [8]. Since the possibility of measuring BF% is not 
always available and the relation between BMI and BF% is highly 
dependent on sex and age, several prediction equations that 
account for sex and/or age have been published. Recently new 
predictive equations that may be used as a first screening tool in 
clinical practice have been published [9].
Obesity pathogenesisObesity is a chronic disease like hypertension and diabetes. Mechanistically is the result of an imbalance between the 
energy ingested in food and the energy expended. As a cause, in addition to a predisposed genetic make-up that promotes fat 
AbstractObesity is a serious, common and growing problem. Obesity can 
be defined as an excess of body fat. Its clinical management is 
complex and frequently unsuccessful. It has only recently been regarded as a chronic disease, linked with diabetes, dyslipidaemia 
and cardiovascular disease. It is increasingly known that obesity is a multifactorial disease; involving genetic determinants that interacting with environmental factors results in obesity. The global epidemic of obesity imposes a major disease burden, particularly cardiovascular 
disease. There is a clear link between adipose tissue and inflammation, object of the present review. Adipose tissue is considered a dynamic 
organ with extremely sophisticated functions. Obesity is associated 
with low chronic inflammation through the secretion of adipokines. 
Inflammation mediates on the development of metabolic diseases associated with obesity, dyslipidaemia, hypertension and type 2 diabetes. The treatment of obesity has evolved, from short time and simple diet together with increase in physical activity to long-term approaches based on changes in eating behavior and physical habits. 
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Introduction
It is often unrecognized that although obesity was included 
in the classic listing of diseases in 1948, the medical profession dismissed it for decades. Two other documents by The London 
Royal College of Physicians published in 1976 and 1983 [1,2] highlighting obesity as a problem that has been ignored also for the medical profession and governments. This was probably related to the fact that obesity was assumed to be a reversible problem, that could be solved if people only eat less and do more 
exercise. This misunderstanding persists today.
However, the perception of adipose tissue has changed considerably with the dramatic increase in the incidence of obesity and in obesity-related co morbidities over the past 2 
decades. Excess fat is no longer associated with wealth, but is 
instead recognized as a risk factor for many diseases. Adipose 
tissue is increasingly being identified as a vital, complex 
endocrine organ, and not simply as a fat store [3]. In this review, 
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deposition, important environmental factors related to nutrient 
composition, sedentary habits and the involvement of complex 
systems of reward might play important roles. We are designed with robust adaptive allostatic systems attempting to maintain a 
specific set point of energy balance. There is evidence that defects in these systems preferentially result in activation of pathways that save energy, making the control of energy balance an almost 
impossible task, with the current available strategies [10]. 
Furthermore, we are exposed to an obesogenic environment 
that includes obesogens [11] together with other factors such as 
disordered eating behaviors [12-14]. All these aspects make the 
development of obesity in humans a complex problem (Figure 1).A variety of endocrine and metabolic changes are associated 
with overweight and obesity [15,16]. Most of these changes are secondary, because they can be induced by overfeeding and 
reversed by weight loss. It is not completely clear if some of these hormonal changes may contribute to the pathophysiology of 
obesity or to perpetuate the obese state. In obesity GH secretion is markedly decreased. The pathophysiological mechanisms 
responsible for the GH hyposecretion of obesity are probably 
multifactorial [15,17] and could contribute to maintain the obese state. There are important data that suggest a preponderant 
role of, the endogenous GH secretagogue, ghrelin in the 
pathophysiological regulation of body weight [18-21].
The results of the afore mentioned factors are that excess 
energy is stored in fat cells that enlarge and/or increase in number. This hyperplasia and hypertrophy of fat cells is the 
pathological lesion of obesity. Enlarged adipose tissue produces the clinical problems associated with obesity, either because of 
the weight or mass of the extra fat or because of the increased secretion of free fatty acids and peptides from fat cells. The 
consequences of these two mechanisms are different diseases, 
such as type 2 diabetes, hypertension, gallbladder disease, osteoarthritis, ischemic heart disease, some types of cancer, 
social and psychological disabilities [22,23]. 
Fat tissue development
In humans, the first fat lobules begin to develop about the 
fourteenth and sixteenth weeks of gestation, with cranial-to-caudal 
and proximal-to-distal gradients [24]. By 28 weeks, fat lobules can be detected in all presumptive visceral and subcutaneous 
white adipose tissue locations [24]. Adipocyte progenitors are derived from multipotent mesenchymal stem cells. These precursor cells are devoid of lipid, but become committed to the adipocyte lineage and are regarded as preadipocytes that have lost the capacity to differentiate into other cell types. The second phase results in the terminal differentiation of these adipocyte progenitors into mature, functional adipocytes.
Peroxisome Proliferator-Activated Receptor (PPARγ) is 
regarded as the master regulator of adipogenesis. PPARγ is a member of the nuclear-receptor super- family, and is both 
necessary and sufficient for adipogenesis [25]. PPARγ is not only 
crucial for adipogenesis, but is also required for the maintenance of the differentiated state.
In addition to adipocytes, adipose tissue contains stromal-
vascular cells, including fibroblastic connective tissue cells, leukocytes, macro-phages, and preadipocytes (that are not yet 
filled with lipids), which contribute to structural integrity and 
constitute around 50% of its total cellular content [26]. The lipid droplets in adipose tissue can be unilocular, multilocular, or both. 
Unilocular cells are characteristics of the white adipose tissue while multilocular cells are typically seen in brown adipose tissue.
Figure 1: Different factors in Obesity ethiopathology.
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Figure 2: Different factors secreted by adipose tissue.
Heterogeneity of adipose tissueThe adipose tissue pool in mammals is composed of at least 
two functionally distinct types of fat: white and brown. White adipose tissue is the primary site of energy storage and the release of hormones and cytokines that modulate whole-body 
metabolism and insulin resistance [27,28]. Additionally, white adipose tissue can act as a thermal insulator and protect other 
organs from mechanical damage [29]. Brown adipose tissue uses the chemical energy in lipids and glucose, to produce heat through non-shivering thermogenesis via mitochondrial uncoupling of 
oxidative phosphorylation of free fatty acids, mediated by the 
expression of tissue-specific, mitochondrial brown fat uncoupling 
protein 1 (UCP1) [30]. Like white adipose tissue, brown adipose tissue can affect whole-body metabolism and its activation might lead to new approaches to promote weight loss and increase 
insulin sensitivity [31,32].There is a regional distribution of adipose tissue. Adipose tissue is located beneath the skin (subcutaneous adipose 
tissue), around internal organs (visceral adipose tissue), in bone 
marrow (yellow bone marrow), and in breast tissue. Conversely, 
peripheral subcutaneous adipose tissue exhibits an independent 
anti-atherogenic effect [33] and is not related to many of the classic obesity-related pathologies, such as cancer, heart disease, and stroke, with some evidence that it might even be protective 
[34].
Cardiac adipose tissue has recently been considered a new 
specific location of adipose cells [3]. The concept of cardiac 
adiposity as cardiovascular risk factor is novel. Epicardial 
adipose tissue is the true visceral fat deposit of the heart [35-37] and is located between the myocardium and visceral pericardium 
around both ventricles varying in extent and distribution pattern 
[36-38]. Pericardial adipose tissue is composed of epicardial 
and pericardial adipose tissue located on the external surface of the pericardium. Both unfavorable and protective have been 
attributed to epicardial adipose tissue [39]. Epicardial adipose 
tissue is an extremely active organ that expresses a higher number 
of inflammatory mediators and chemokines than subcutaneous 
adipose tissue, irrespective of BMI [40]. Epicardial adipose tissue 
thickness is an independent predictor of visceral adiposity [41]. 
Furthermore, a clear positive correlation was reports between epicardial adipose tissue volume and coronary artery calcium 
score in several studies [42-44].
Adipose tissue as endocrine organ
White adipocytes are major secretary cells [45], which makes 
adipose tissue a key endocrine organ. Indeed, adipose tissue is 
the largest endocrine organ in most humans [28] and is certainly 
so in individuals who are overweight or obese. For example, 
approximately 20% of total body weight is adipose tissue in an individual who is lean whereas adipose tissue constitutes almost half of body weight in a person who is obese. 
White adipose tissue has been identified as a metabolically active endocrine organ that affects a plethora of body functions including energy and feeding regulation, glucose and lipid metabolism, thermogenesis, neuroendocrine function, reproduction, immunity and most relevantly cardiovascular function. These effects are achieves via the release of important chemical mediators, hormones and adipocytokines or 
adipokines. The discovery of leptin in 1994 heralded a new era in the study of adipose tissue. Other proteins that are secreted by adipose tissue with important metabolic effects include a number of adipocytokines, such as adiponectin, leptin, resistin, visfatin, apelin, omentin, chemerin, nesfatin and other cytokines, 
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e.g. Interleukin-6 (IL6), Plasminogen Activator Inhibitor (PAI-
1), Monocyte Chemo Attractant Protein 1 (MCP-1) and Tumor 
Necrosis Factor-α(TNF α). Many others have now been identified 
and the list is growing [46-47] (Figure 2).
Adipose tissue and inflammation
Adipocytes have intrinsic inflammatory properties. They 
express multitude of receptors to which pathogens and 
inflammatory signals bind. In turn, the receptors can induce 
the secretion of various potent inflammatory cytokines and 
mediators. Adipocytes express receptors for TNF (TNF receptor 
superfamily member 1A [also known as p55] and 1B [also known 
as p75] and the mammalian lipopolysaccharide-activated toll-
like receptor 4. Binding to these receptors activates nuclear 
factor NF-κB signal transduction pathways [48]. Adipocytes 
may initiate inflammatory signaling cascades upon activation 
by IL-1β, IL-4, IL-6, IL-11, interferon-γ, and fungal cell-wall 
components [49]. As well as reacting to several mediators 
of inflammation, adipocytes can induce the expression and 
secretion of mediators of inflammation, including complement 
factors B, C3, and D, haptoglobin, hepatocyte growth factor, IL-1β, 
IL-6, IL-8, IL-10, IL-15, leukemia inhibitory factor, macrophage 
migration inhibitory factor, prostaglandin E2, serum amyloid 
A3 protein, and TNF, as well as Adiponectin, Apelin, Chemerin, 
Leptin, Resistin, Serpin A12 (also known as vaspin), and visfatin 
[50]. Adipocytes are not the only cells in adipose tissue to 
elicit inflammatory responses; resident macrophages can also 
secrete inflammatory mediators. These macrophages can act 
independently or synergistically to stimulate inflammation. In addition, the adipose tissue macrophages in diet-induced obesity 
tend to have a pro-inflammatory (M1) phenotype, involving IL-6, 
IL-12, and TNF [51]. Furthermore, the adipocytes in individuals who are obese are larger than those in people of average weight, and produce a lower level of adiponectin, but higher levels of 
pro-inflammatory cytokines such as TNF. Therefore, obesity is 
associated with systemic inflammation.
Despite using similar pathways and mediators, the 
inflammatory response in obesity differs substantially in duration and intensity from that observed in the more familiar setting of 
infection. For instance, infectious inflammation involves short-
lived high-amplitude responses, whereas metabolic inflammation 
like other chronic inflammatory conditions smoulders at low levels for years to decades. Although the underlying mechanisms contributing to these differences are not entirely clear, it seems likely that hormonal or epigenetic programming may permanently 
reassign certain systemic and tissue-specific parameters, such as 
body weight and leukocyte activation, in obesity [52].
Inflammatory activation within metabolic tissues potentiates 
insulin resistance and metabolic disease [52].Obesity-induced 
metabolic disease promotes and exacerbates pathology through 
numerous disease-specific mechanisms; most metabolic disease ultimately arises from obesity’s characteristic milieu of chronic 
low-grade inflammation and insulin resistance. For example, 
obesity has been recognized for decades as an important risk 
factor for cardiovascular disease; however, only recently has that risk been mechanistically understood as a result of obesity’s 
accompanying inflammation and insulin resistance [53]. 
Similarly, hyperlipidaemia, another well-described contributor to 
cardiovascular disease, arises as a consequence of inflammatory insulin resistance through increased adipose tissue lipolysis 
and hepatic lipogenesis. Even the biomechanical dynamics 
of cardiovascular disease, atherosclerotic plaque formation, 
remodelling, and rupture are influenced by the inflammatory 
milieu [53]. Indeed, the efficacy of some antihyperlipidemic therapies, statins and salicylates, correlates with their immunomodulatory potency as much as with their lipid-lowering 
capacity [54].
Treatment of the Obese Patient Nowadays, obesity is a major health problem because its prevalence is progressively increasing and there is no indication that current strategies may solve the problem in the near future. 
In order to treat overweight and obese patients, any intervention that causes a negative energy balance is effective in producing weight loss. This is the basis for the classical use of short-term restrictive diets, resulting mainly in loss of body water and 
muscle mass, followed by a rapid body weight regain. When treating obese subjects we should bear in mind that obesity is 
defined by increased body fat, and to reduce such increase of 
body fat should be our treatment target. It is also important that health professionals consider the obese patient as chronic; 
consequently the treatment should be programmed for a long period of time.
Emerging evidence support the notion that long-term balanced diet together with increase physical activity can reduce 
adiposity [55,56]. How can we achieve long-term modification of 
life-style? Since is well known that change of habits in adults is a 
very difficult task, Educational therapy and Psychotherapy may 
help us to obtain positive results [57-59].
In order to treat overweight and grade I obesity it could be enough with the use of a life-style change program, in some 
cases with the concurrence of behavioral education [58] or 
psychotherapy [59]. While for grade II and III obese patients, 
at the beginning of the diagnostic process the existence of 
concomitant psychological anomalies should be ruled-out [11-
13].Thereafter, the help of a psychotherapist can be useful to 
facilitate the change of habits [57-61]. In these cases some drugs can be used as adjuvant treatment. 
Pharmacotherapy can be used as adjunct (not as substitute) 
to lifestyle modification. The number of drugs available for the treatment of obesity has decreased in recent years because 
some of them, in particular dexfenfluramine and sibutramine have been removed from market as a result of serious side 
effects [62]. The anti-obesity drugs presently on the market in 
USA are Benzphetamine, Phendimetrazine, Phentermine and 
Diethylpropion for short-term use. For long-term use were 
approved Orlistat and recently Phentermine/Topiramte and 
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Lorcaserin, while in development Bupropion/Naltrexone and 
Liraglutide [63]. Furthermore, drugs such as fluoxetine use for 
anxiety control or anticonvulsant as topiramate can help at least 
temporally [64].
For patients with Grade III obesity the first line of treatment 
is bariatric surgery. The question is what modality of this kind 
of surgery should be use in each patient? In general several 
factors should be taken into account: first the surgeon expertise, the preference of the patient, and it should be bear in mind that obesity is a long-term process and that surgical intervention is not 
an etiological treatment. For these reasons it could be adequate in 
young patients to propose first a less complex intervention, such 
as reduction techniques, if weight regain occurs, another more 
complex intervention can be used such as by-pass techniques 
[65-67] (Figure 3).
However, bariatric surgery is not free of complications that 
are related to the procedure performed. Perioperative death 
after surgery for obesity occurs in about 2 per 1,000 of operated 
patients in population based-studies [68]. The more complicated 
the procedure the higher risk of perioperative death. Dysphagia may occur after laparoscopic adjustable gastric banding. An 
anastomotic leak after laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy is a life-threatening 
complication. Gallstone disease is common after surgery for 
obesity with incidences up to 50% [69]. Furthermore, after 
all surgical procedures some degree of nutritional deficiency 
exists, therefore all patients need lifelong vitamin and mineral 
substitution. The possibility of weight regain after time exist specially after pure restrictive procedures.An important aspect, as in any chronic disease, is the training of the patient, in order to the future self-care of their disease. This part of treatment promotes the patient autonomy and reduces 
the cost of long-term treatment. Finally, prevention of obesity 
must be a public health priority; it has been found that specific 
lifestyle and dietary factors are associated with marked weight gain, with a substantial aggregate effect and implications for 
strategies to prevent weight gain [70,71]. 
Effects of obesity treatment on patients health
Even modest weight loss of 5% to 10% of the patients starting 
weight can lead to significant health benefits. People with 
hypertension who lost a modest 10 pounds over 6 months reduce 
their systolic pressure by 2.8 mm Hg and their diastolic pressure 
by 2.5 mm Hg, these reductions were equivalent to reductions of blood pressure induced by some blood pressure medications. 
Major trials showed the benefits of lifestyle changes, including 
losing weight and exercising [72,73]. More recent evidence showed that lifestyle intervention was effective in promoting weight loss and improving cardiovascular disease risk factors 
[74,75].
Regarding to the effect of obesity treatment on inflammatory components, increased epicardial adipose tissue is associated with several features of metabolic syndrome, including 
significant correlations with the levels of adiponectin, arterial 
blood pressure, fasting insulin, and LDL cholesterol [40]. Weight loss can be associated with a reduction in epicardial adipose 
tissue thickness in individuals who are severely obese [76]. This 
would be a beneficial effect, since growing evidence shows that epicardial adipose tissue might be implicated in the pathogenesis of arrhythmias, coronary artery disease, diastolic dysfunction, myocardial hypertrophy, and valvular disease.
Conclusion
Increase knowledge relating to the diverse structures and 
functions of adipose tissue are available today. Contrary to the past, adipose tissue is considered a dynamic organ with 
extremely sophisticated functions. Obesity is associated with 
low chronic inflammation through the secretion of adipokines. 
Evidence exists for the role of inflammation on the development 
Figure 3: Treatment of obesity according to the degree of adiposity.
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of metabolic diseases associated with obesity, such as dyslipidaemia, hypertension and type 2 diabetes. The treatment of obesity has evolved, from short-time and simple diet together with increase in physical activity, to long-term approaches based on changes in eating behavior and physical habits, with the aim of obtaining a slow and sustained decrease in fat mass, avoiding the regain of body weight of the classic treatment.
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